UK first approves Astra vaccine for emergency use

The first vaccine to enter Korea
British authorities “Effects on mutated corona
US-EU still doubts credibility
The UK is the first in the world to approve the urgent use of a novel coronavirus infection (Corona 19) vaccine developed by its domestic pharmaceutical company AstraZeneca on the 30th (local time), and it will be vaccinated from the 4th of the following month. However, AstraZeneca has not fully resolved the questions that have been raised about the vaccines developed so far, and the European Union and US health authorities are still showing doubts about the reliability of the vaccine. The AstraZenega vaccine is expected to be the first vaccine that Korea intends to introduce, but the government expects to introduce it as early as the first quarter of next year. The government has signed a contract to purchase 10 million people of this vaccine.

In a statement that day, the UK Ministry of Health said, “Accepting the recommendations of the Pharmaceutical and Health Care Product Regulatory Agency (MHRA), it approved the emergency use of the AstraZeneca vaccine. In addition, he said, “We decided that giving the first vaccination to those in the high-risk group as much as possible is more important than getting all the second vaccinations in a short period of time.” The reliability of the vaccine is also important, but the focus was on rapid approval. .

According to the BBC, Health Minister Matt Hancock said, “We have secured a total of 100 million doses and will be given 4 million doses first, starting on the 4th of next month.” Prime Minister Boris Johnson also tweeted, “It is a victory for British science and will vaccinate as many people as possible.”

Secretary Hancock said the vaccine is also effective against a mutant virus that has recently terrorized the world. However, the EU health authority, the European Medicines Agency (EMA) said the day before, “AstraZeneca has not yet submitted an application for approval. It is too early to determine whether to use it because we need more information about the vaccine. The US Food and Drug Administration (FDA) is also questioning the clinical results, CNN said. Last month, AstraZeneca reported that’the prevention rate was 62% when the entire dose of the vaccine was administered twice, and the prevention rate was 90% when the entire dose was administered in the second dose after the first dose.’ The intermediate results of the phase experiment were announced. Many medical experts have questioned, but they have not been able to clearly explain why the ‘0.5+1’ method is more effective than ‘1+1’.

Paris = Correspondent Yunjong Kim [email protected]Go to reporter page>